Skip to main content
Fig. 3 | Allergy, Asthma & Clinical Immunology

Fig. 3

From: Expression of COX-1, COX-2, 5-LOX and \(\hbox {CysLT}_2\) in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease

Fig. 3

COX-2 immunoreactivity (IRS). Results of the staining of nasal (a–c) and bronchial (d–f) samples for COX-2 are shown as boxplot diagrams. The lower and upper boundaries indicate the 25% and 75% quartile, respectively. Minimum and maximum values are indicated as whiskers and the dot represents the group median. Outliers were plotted as individual points. a Nasal respiratory epithelium (AIA: \(n=23\), ATA: \(n=17\), NPwA: \(n=15\)), b nasal submucosal glands glands (AIA: \(n=19\), ATA: \(n=16\), NP: \(n=15\)) and c) nasal squamous epithelium (AIA: \(n=13\), ATA: \(n=13\), NPwA: \(n=12\)), without significant differences in patient group comparisons. d Bronchial respiratory epithelium (AIA: \(n=14\), ATA: \(n=13\), NPwA: \(n=8\)), e bronchial submucosal glands (AIA: \(n=7\), ATA: \(n=8\), NPwA: \(n=5\)) and f bronchial squamous epithelium (AIA: \(n=13\), ATA: \(n=11\), NPwA: \(n=7\)), without significant differences in patient group comparisons

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us